TTUHSC School of Medicine
HomeSchool of MedicinePharmacology and NeuroscienceFacultyDr. Bergeson

Pharmacology and Neuroscience

Bergeson Header

bergesonDr. Susan E. Bergeson
Director, Biotechnology
Associate Dean, Graduate School of Biomedical Sciences
Associate Professor, Pharmacology and Neuroscience
Distinquished University Professor
Graduate Student Adviser, Biotechnology

Ph.D., 1997 - Oregon Health & Science University

Office:  5B148C         
Phone:  806-407-9930
Lab:  5B148A, E & H
Lab Phone:  806-743-3497
FAX:  806-743-2744

GSBS Program Affiliations:  
MS - Biotechnology
PhD - Translational Neuroscience and Pharmacology

* Dr. Bergeson is not accepting students at this time




Genetics and Molecular Neurobiology of Alcohol Abuse and Alcoholism:

Through the use of bioinformatics technology applied to global mRNA and miRNA analyses of several genetic mouse models of alcohol consumption and dependence, Dr. Susan Bergeson's lab, together with her collaborators, have uncovered new genes and biological pathways not previously known to be involved in alcohol-related behaviors and responses. A recent, important contribution to the field was the identification of age-divergent alcohol-induced neuroimmune responses as a druggable target in adult high-alcohol consuming mice. The lab has successfully tested neuromodulatory drugs that significantly reduced drinking in adult mice, but whose effects are apparently blocked by miRNA expression changes in the adolescent brain. As one of few alcohol researchers focused on sex as an important factor in alcohol responses, Dr. Bergeson has identified differences in consumption and dependence at the behavioral, physiological, molecular and epigenetic levels. Most importantly, variation between females and males in the pharmacological efficacy to reduce the negative aspects of alcohol has been identified. The long-term goal of the lab is to use an amalgamation of behavioral, biochemical, molecular, neuroanatomical and pharmacological methods to better understand and treat Alcohol Use Disorder with a personalized, sex-specific, medications approach. Toward that end, we have recently filed patent protection for a new use for tigecycline, which reduces binge and dependence-mediated drinking and alcohol withdrawal seizures.


NIH, 1R21 AA021142 - Neuroimmune Interactions in High Alcohol Drinking
The Bryan C. Miller, Jr. and Martha H. Miller Foundation, Inc - Understanding Alcohol Use Disorder
TTU-TTUHSC Presidents' Collaborative Research Initiative - Investigating Translational Strategies in Fetal Alcohol Spectrum Disorder and Alcohol Use Disorder in a Novel Porcine Model

Bergeson Lab Members:

Bergeson Lab